Mode
Text Size
Log in / Sign up
N/A N=51 Randomized Treatment

Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1

Alcohol Use · Drug Use · Risk Behavior · Sexual Behavior

Enrolled (actual)
51
Serious AEs
39.2%
Results posted
Dec 2016
Primary outcome: Primary: Percentage of Monthly Urine Samples That Are Negative for Cocaine — 51.8; 79.3 percentage of urine samples — p=.004

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Contingency management (Behavioral); Employment Only (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Johns Hopkins University
Primary completion
Aug 2007

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Monthly Urine Samples That Are Negative for Cocaine
51.8; 79.3 .004 sig
SECONDARY
Percentage of Monday, Wednesday and Friday Urine Samples That Are Negative for Cocaine
SECONDARY
Percentage of 30-day Assessment Urine Samples Negative for Opiates
90.6; 88.6 =0.57
SECONDARY
Percentage of Monday, Wednesday and Friday Urine Samples That Are Negative for Opiates
SECONDARY
HIV Risk Behaviors
16.7; 0 0.046 sig

Summary

This application is a competing continuation of a grant in which we developed and pilot tested a computerized Therapeutic Workplace designed to train and employ adults as data entry operators. A randomized trial is planned over 5 years to investigate the Therapeutic Workplace business as a maintenance intervention to sustain long-term abstinence and employment. Welfare recipients in methadone treatment, actively using cocaine, and at risk for contracting or spreading HIV infection will participate in an initial Therapeutic Workplace training phase. Participants who become abstinent and skilled will be randomly assigned to an Abstinence & Employment, or an Employment Only group. Participants in the Abstinence & Employment group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary. Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work. This study will provide a rigorous evaluation of the efficacy of the Therapeutic Workplace business as a long-term treatment of cocaine addiction and unemployment; determine the benefits of requiring daily evidence of abstinence to work; and provide information on the extent to which a Therapeutic Workplace business can become self-sustaining. This research could provide firm scientific foundation for the dissemination of Therapeutic Workplace businesses in the long-term treatment of cocaine addiction and unemployment. The main hypothesis being tested is that cocaine abstinence will be reliably maintained during the yearlong intervention evaluation period only in the group exposed to the explicit abstinence maintenance intervention. We expect that cocaine abstinence in the Abstinence and Employment group will be significantly greater than cocaine abstinence in the Employment Only group.

Eligibility Criteria

Inclusion Criteria

  • Applicants in methadone treatment may be eligible to participate in Phase 1 of the study.
  • Applicants will be blind to the full details of the eligibility criteria.
  • Unemployed
  • Provided a urine sample at intake with a detectable concentration of cocaine metabolite or provided a cocaine positive sample during regular urinalysis testing at a methadone maintenance program
  • Met DSM-IV criteria for cocaine dependence
  • Were receiving welfare benefits in Baltimore, MD
  • Received a score of less than or equal to 80% correct on a reading assessment

Exclusion Criteria

  • Being at imminent risk for suicide
  • Reported hallucinations
  • Being incarcerated or otherwise under constant monitoring
  • Earned less than or equal to $200 in unreported taxable income from legal activity in the previous month
  • Having physical limitations that prevented typing
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00249496). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search